MUC1 and neoplasm: Based on the aspects such as therapeutic function, immunogenicity, specificity, and expression level, the NCI Translational Research Working Group prioritized MUC1 as the second‐best potential target out of 75 tumor‐associated antigens for the development of cancer vaccines.7